Respiratory Issues Complicated by Economic Disadvantage
Socio-economic status, commonly referred to as SES can be describes as the economic or social standing of an individual, and is a measure of the person’s economic or social position in a social group. SES is a composition of different measures such as education, earnings, location of housing or job. According to studies, a lower socio-economic status can be related to unequal access to healthcare in several illnesses. There exists emerging data and information on respiratory diseases such as asthma, COPD, pulmonary hypertension, cystic fibrosis and other pulmonary ailments which suggest a similar observation also noticed in other chronic ailments (Sahni, Talwar, Khanijo & Talwar, 2017).

Asthma is a chronic inflammatory illness that presents permanent condition with varying severity levels all through the life of the affected persons. It affects individuals of all ages and presents its highest frequency in childhood. Latest data gathered from the general population reveal that kids up to the age of 5, the average frequency rate of asthma was 23 per 1,000 kids annually; this frequency rate dropped amongst the youth aged between the ages of 12 to 17 to 4.4 per 1,000 persons annually. Grownup females had 1.8 times higher asthma frequency compared to grownup males; 4.9 per 1,000 versus 2.8 per 1,000, respectively (Winer, Qin, Harrington, Moorman & Zahran, 2012). In the USA, according to the NHIS (National Health Interview Survey) -2012, approximately 40 million individuals (13 percent of the population in USA) were affected by lifelong asthma and 26 million individuals (8 percent of the population) suffered from current asthma. The incidence of lifelong asthma in different nations was approximated to vary between 1 to 18 percent of the entire population (Nunes, Pereira & Morais-Almeida, 2017).

SES is a significant determinant of not only nutritional and health status but also morbidity and mortality. It also affects the affordability, acceptability, accessibility as well as the actual use of different available health amenities. Numerous researches have been carried out to determine the relationship between SES and health related issues (Kant, 2013). The extent and nature of poverty varies between societies. In the Unites States of America, financial obstacles might hinder the poor from acquiring suitable care and might constrain the ability to buy medicine. High outdoor and indoor pollution, smoking, low birth weight, preterm delivery, obesity, size of family, ethnic background and diet which, in different extents, have been found to be linked to asthma, are also related to poverty (Rona, 2000).

Additionally, the kid might be suffering from COPD (Chronic Obstructive Pulmonary Disease). COPD is among the most common lifelong pulmonary disorders and numerous studies have found its incidence to be more in the lower socio-economic status population. In one of the earliest studies by NHANES surveys, Whitemore et al., (1995) reported a major inverse relationship between COPD and earnings for both males and females. Numerous authors discovered that household earnings was a significant determinant of COPD incidence and the COPD incidence was considerably higher amid individuals...…and theophylline were previously active ingredients contained in non-prescription asthma drugs. Both of them are now, however, categorized prescription-only drugs. The FDA has taken several actions concerning the control of non-prescription drugs for asthma over the last thirty years. Back in 1976, it established that inhaled epinephrine offered effective and fast relief in moderate to mild asthma patients. In 1982, the FDA again concluded a provisional final monograph: epinephrine hydrochrolide, epinephrine bitartrate and epinephrine in a pressurized metered-dose inhalation aerosol dosage forms could be generally identified as effective and safe for OTC usage at a certain dose for grownups and kids of more than 4 years of 1-2 inhalations of a metered-dose equivalent of 0.16-0.25 milligrams epinephrine per inhalation not exceeding every three hours.

The FDA reviewed ephedrine medications back in 1986 for bronchodilation and approved ephedrine to be generally effective and safe for non-prescription usage. In that same year, the FDA concluded that there was not enough data to restrict inhaled epinephrine to prescription only. It concluded that revised and expanded labeling would greatly benefit users.

Following a number of reports deaths and life-risking events related to non-prescription combination drugs containing theophylline, the Food and Drug Administration issued a final verdict in 1995 that these drugs were not effective or safe. Hence, drugs containing this combination (theophylline and ephedrine) were discontinued. Additionally, in 1995, the FDA suggested removing ephedrine from the non-prescription market because of its role in the production of methcathinone and methamphetamine as well as its misuse in muscle…